Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Gemcitabine Chemotherapy Compound

About this update from Helix Biopharma Corp.

[{"type":"text","content":"Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Gemcitabine Chemotherapy Compound\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n December 2, 2024 –\n \n\n TheNewswire –\n \n\n (Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”,\nOTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (\n \n\n “Helix”\n \n\n or the\n \n\n “Company”\n \n\n ), a clinical-stage biopharmaceutical company developing\nnovel therapies in immune-oncology, based on its proprietary\ntechnological CEACAM6 platform, DOS47, is pleased to announce it has\nentered into an asset purchase agreement dated November 30, 2024 (the\n \n\n “Agreement”\n \n\n ) with Laevoroc Chemotherapy AG\n \n\n (“Laevoroc Chemotherapy”\n \n\n ), a privately-held Swiss company.\n \n\n\n\n Pursuant to the transaction (the “\n \n\n L-Chemo Transaction\n \n\n ”),\n \n\n Helix will acquire the\nintellectual property, inventory, assigned agreements and rights to\n \n\n GEMCEDA\n \n\n ,\nan oral gemcitabine chemotherapy combined with cedazuridine that\nnear-matches the bioavailability of its intravenous counterpart, while\nproviding a more tolerable treatment regimen for patients with\nprevalent, hard-to-treat cancers. Gemcitabine is a World Health\nOrganization (WHO) Essential Medicine and GEMCEDA is a patented\nprodrug in preclinical development to offer a spectrum of\ndisease-limiting and life-enhancing treatment outcomes for these\npatients.\n \n\n\n\n Through the L-Chemo Transaction,\n \n\n Helix will acquire substantially all the assets and certain\nliabilities of Laevoroc Chemotherapy for 13.5% of Helix’ issued and\noutstanding common shares\n \n\n\n\n upon closing.\n \n\n If the L-Chemo\nTransaction were to close today, Helix would be required to issue\n6,617,907 common shares (the “\n \n\n L-Chemo Consideration Shares\n \n\n ”), based on\nthe 49,021,536 shares currently issued and outstanding. All shares\nissuable under the L-Chemo Transaction will be subject to a hold\nperiod of four months and one day from the issuance date.\n \n\n\n\n TSX/Shareholder Approval\nRequirements\n \n\n\n\n Helix entered into an asset purchase agreement dated\nNovember 28, 2024 with Laevoroc Immunology AG (“\n \n\n L...

More updates from Helix Biopharma Corp.